The burden of chronic rhinosinusitis with nasal polyps

CRS is an inflammatory condition of the upper airways[1]



CT image of a patient with severe CRSwNP[5]

Estimates of global CRS prevalence vary: >10% of the population has been estimated to have CRS based on symptomatic or objective evidence, while the presence of both has produced estimates of **<5%**.[1]

CRS with nasal polyps (CRSwNP) represents **18–30%** of all cases of CRS.[1-3]

CRSwNP is characterized by the presence of nasal polyps and chronic sinonasal inflammation, which can result in symptoms such as:[4]


Nasal congestion


Nasal discharge


Facial pain/pressure


Impaired sense of smell

CRSwNP is characterized by a decreased quality of life, and it places a significant psychological and social burden on patients[6,7]

Quality of life can be further reduced for patients with CRSwNP and comorbid asthma.[8]

CRSwNP represents heterogeneous, and often overlapping, endotypes[9]

CRSwNP can be divided into **three endotypes** based on the inflammatory profiles associated with **specific immune cells**, **cytokines**, and **dominant clinical features**:[10]

Type 1	Type 2	Type 3
IFN-γ and IL-12[10]	**IL-4, IL-5, and IL-13**[10]	**IL-17 and IL-22**[10]
ILC1, NK cells, Th1 cells, CD8+ T cells, and M1 macrophages[10]	**ILC2, eosinophils, basophils, mast cells, Th2 cells, and M2 macrophages**[10]	**ILC3, neutrophils, and Th17 cells**[10]
Headache and facial pain[9]	**Loss of sense of smell and comorbid asthma**[9-11]	**Purulent rhinorrhea**[9-11]

- In the US, **Type 2** is the most common endotype of CRSwNP.[10]
- Many patients with CRSwNP have a **mixed endotype**, and ~9% have **no clear endotype**.[9,11a]

Despite medication and surgery, many patients with CRSwNP have uncontrolled disease[15]


In a survey of **437 physicians**, **70%** reported that **OCS** provide only **temporary symptom relief** in CRSwNP.[16]


38% of patients (n=125) experienced **polyp recurrence** 12 months after medical therapy and sinus surgery.[15c]


~80% of patients with CRSwNP (n=212) experienced **inadequately controlled symptoms** within 3 to 5 years after surgery.[17d]

CRSwNP is frequently associated with asthma[8]

Up to 67% of patients with **CRSwNP** have **comorbid asthma**[8b]

8–21% of patients with **severe asthma** have a history of **nasal polyps**[12,13]

In asthmatic patients, comorbid CRSwNP is associated with increased exacerbation frequency, increased symptom severity, and reduced quality of life.[8,14]

Did you know?[18]

- **NPS** is often used as a primary outcome in clinical trials for CRSwNP.
- NPS uses endoscopy to assess **polyp size** in each nostril, ranging from 0 to 4.
- Total NPS is the sum of the scores for each nostril (0–8); **higher scores indicate more severe disease**.

[a]Patients without a clear endotype are defined as those expressing biomarkers below detection thresholds;[9,11] [b]Range: 40–67%;[8] [c]Medical therapy included, but was not limited to, at least one course of either topical corticosteroids or a course of OCS therapy and at least one course of broad-spectrum or culture-directed antibiotics;[15] [d]Control was assessed using mean total VAS, SNOT-22, and SF-36 scores in patients with CRSwNP 3–5 years after FESS.[17]

CRS, chronic rhinosinusitis; CRSwNP, chronic rhinosinusitis with nasal polyps; CT, computed tomography; EMT, epithelial-mesenchymal transition; FESS, functional endoscopic sinus surgery; IFN, interferon; IL, interleukin; ILC, innate lymphoid cell; NK, natural killer; NPS, nasal polyp score; OCS, oral corticosteroid(s); PRR, pattern recognition receptor; SF-36, Short Form 36-item Health Survey; SNOT-22, Sino-Nasal Outcome Test-22; Th, T helper; tPA, tissue plasminogen activator; TSLP, thymic stromal lymphopoietin; VAS, visual analog scale.

EpiCentral
UNDERSTANDING THE CENTRAL ROLE OF THE EPITHELIUM IN SEVERE ASTHMA AND BEYOND

Veeva ID: GB-59019; date of preparation: September 2024.

AstraZeneca

The central role of the epithelium in CRSwNP

The nasal epithelium is significantly altered in CRSwNP and plays a critical role in the disease[19]



Role of epithelial cytokines in CRSwNP

Epithelial cytokines are released in response to environmental irritants, such as allergens, pathogens, and pollutants.[26]



TSLP, **IL-25**, and **IL-33** are increased in nasal mucosal epithelial tissue from patients with CRSwNP compared with controls, with the highest levels observed in eosinophilic CRSwNP.[26]

TSLP, the TSLP receptor, and the IL-33 receptor correlated with increased disease severity and Type 2 inflammation[27]



Disruption of the epithelium augments inflammation and is central to nasal polyp formation:

A Epithelial damage triggers EMT; mesenchymal cells alter inflammatory and remodeling processes.[23,24]

B Epithelial cytokines TSLP and IL-33 drive multiple downstream processes, including mast cell activation and production of IL-4, IL-5, and IL-13.[20]

C Mast cells and basophils drive mucosal edema, resulting in plasma leakage.[20]

D Cross-linked fibrin forms a dense mesh and promotes edema.[20,22]

E Elevated IL-4 and IL-13 suppress the expression of tPA and prevent breakdown of fibrin.[20,25]

Did you know?

CRSwNP and asthma share similar features of **airway remodeling and inflammation**.[28,29]

Fibrosis and matrix deposition[28] | Impaired mucociliary clearance[28] | Immune cell infiltration[28] | Epithelial cytokine production[29] | Impaired epithelial integrity[28]

Their shared pathophysiology and frequent co-occurrence support the concept of **united airways disease**, in which the upper and lower airways are linked anatomically, histologically, and immunologically.[30-32]

1. Sedaghat AR, et al. *J Allergy Clin Immunol Pract*. 2022;10:1395-1403; 2. Benjamin MR, et al. *J Allergy Clin Immunol Pract*. 2019;7:1010-1016; 3. Stevens WW, et al. *J Allergy Clin Immunol Pract*. 2016;4:565-572; 4. Orlandi RR, et al. *Int Forum Allergy Rhinol*. 2021;11:213-739; 5. Schleimer RP. *Annu Rev Pathol*. 2017;12:331-357; 6. Bachert C, et al. *J Asthma Allergy*. 2021;14:127-134; 7. Mullol J, et al. *J Allergy Clin Immunol Pract*. 2022;10:1434-1453.e9; 8. Laidlaw TM, et al. *J Allergy Clin Immunol Pract*. 2021;9:1133-1141; 9. Hao D, et al. *J Inflamm Res*. 2022;15:5557-5565; 10. Staudacher AG, et al. *Ann Allergy Asthma Immunol*. 2020;124:318-325; 11. Stevens WW, et al. *J Allergy Clin Immunol Pract*. 2019;7:2812-2820.e3; 12. Reddel HK, et al. *Eur Respir J*. 2021;58:2003927; 13. Scelo G, et al. *Ann Allergy Asthma Immunol*. 2024;132:42-53; 14. Denlinger LC, et al. *Am J Respir Crit Care Med*. 2017;195:302-313; 15. DeConde AS, et al. *Laryngoscope*. 2017;127:550-555; 16. De Corso E, et al. *J Pers Med*. 2022;12:897; 17. van der Veen J, et al. *Allergy*. 2017;72:282-290; 18. Gevaert P, et al. *Allergy*. 2023;78:912-922; 19. Petalas K, et al. *Int J Mol Sci*. 2023;24:12379; 20. Kato A, et al. *J Allergy Clin Immunol*. 2022;149:1491-1503; 21. Saitoh T, et al. *Rhinology*. 2009;47:275-279; 22. Takabayashi T, Schleimer RP. *J Allergy Clin Immunol*. 2020;145:740-750; 23. Chiarella E, et al. *Int J Mol Sci*. 2020;21:6878; 24. Wang Y, et al. *Sci Rep*. 2024;14:2270; 25. Hulse KE, et al. *Clin Exp Allergy*. 2015;45:328-346; 26. Zhang M, et al. *Int Immunopharmacol*. 2023;121:110559; 27. Liao B, et al. *Allergy*. 2015;70:1169-1180; 28. Siddiqui S, et al. *J Allergy Clin Immunol*. 2023;152:841-857; 29. Patel NN, et al. *Int Forum Allergy Rhinol*. 2019;9:93-99; 30. De Corso E, et al. *J Pers Med*. 2022;12:846; 31. Fokkens W, Reitsma S. *Otolaryngol Clin North Am*. 2023;56:1-10; 32. Jakwerth CA, et al. *Cells*. 2022;11:1387.

EpiCentral
UNDERSTANDING THE CENTRAL ROLE OF THE EPITHELIUM IN SEVERE ASTHMA AND BEYOND

AstraZeneca